Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas S Lin

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantationMehdi Hamadani, Craig C Hofmeister, Buffy Jansak, et al.
Leukemia & Lymphoma|October 29, 2009
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemiaThomas S Lin, Louie Naumovski, Philip S Lecane, et al.
JCO Oncology Practice|February 9, 2023
Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion CentersScott A Soefje, Corinne Carpenter, Katherine Carlson, et al.
British Journal of Haematology|March 14, 2012
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphomaMyron S Czuczman, Georg Hess, Ole V Gadeberg, et al.
Blood Advances|February 19, 2021
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFINPeter M Voorhees, Cesar Rodriguez, Brandi Reeves, et al.
British Journal of Haematology|December 18, 2009
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive diseaseJennifer A Woyach, Nyla A Heerema, John Zhao, et al.
Cancer|February 27, 2010
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemiaNeil E Kay, Wenting Wu, Brian Kabat, et al.
The Oncologist|April 24, 2022
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple MyelomaAndrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Susan O'Brien, Ian W Flinn, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantationMehdi Hamadani, Craig C Hofmeister, Buffy Jansak, et al.
Leukemia & Lymphoma|October 29, 2009
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemiaThomas S Lin, Louie Naumovski, Philip S Lecane, et al.
JCO Oncology Practice|February 9, 2023
Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion CentersScott A Soefje, Corinne Carpenter, Katherine Carlson, et al.
British Journal of Haematology|March 14, 2012
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphomaMyron S Czuczman, Georg Hess, Ole V Gadeberg, et al.
Blood Advances|February 19, 2021
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFINPeter M Voorhees, Cesar Rodriguez, Brandi Reeves, et al.
British Journal of Haematology|December 18, 2009
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive diseaseJennifer A Woyach, Nyla A Heerema, John Zhao, et al.
Cancer|February 27, 2010
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemiaNeil E Kay, Wenting Wu, Brian Kabat, et al.
The Oncologist|April 24, 2022
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple MyelomaAndrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Susan O'Brien, Ian W Flinn, et al.
Pageof 8